Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort ascending
Lonsurf trifluridine and tipiracil Metastatic colorectal cancer Reimburse with clinical criteria and/or conditions Active
Lumakras sotorasib KRAS G12C-mutated advanced NSCLC Do not reimburse Active
Trecondyv treosulfan Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) Reimburse with clinical criteria and/or conditions Active
Beqvez fidanacogene elaparvovec Hemophilia B Reimburse with clinical criteria and/or conditions Active
Rezurock belumosudil Graft-versus-host disease Reimburse with clinical criteria and/or conditions Active
Bylvay odevixibat Progressive familial intrahepatic cholestasis (PFIC) Reimburse with clinical criteria and/or conditions Active
Opdualag nivolumab and relatlimab unresectable or metastatic melanoma Reimburse with clinical criteria and/or conditions Active
Columvi glofitamab Relapsed or refractory diffuse large B-cell lymphoma Reimburse with clinical criteria and/or conditions Active
Trodelvy sacituzumab govitecan HR+, HER2− advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Active
Akeega niraparib abiraterone acetate Metastatic castration-resistant prostate cancer (mCRPC) Reimburse with clinical criteria and/or conditions Active